Biotech News & Trading Forum: Community User: Weedmaster

Wegen dem offering war der Absturz

https://finance.yahoo.com/news/spectrum-pharmaceuticals-announces-pricing-public-110000453.html

https://finance.yahoo.com/news/top-analysts-bet-3-penny-152339380.html

Mal anschauen 😁

Nee, da bin ich vollkommen uninformiert.

👍😁 Dann bestimmt auch in spectrum 😉

Zu BCRX: https://msmoneymoves.com/2020/08/04/biocryst-pharmaceuticals-nasdaq-bcrx-an-embarrassment-of-riches/

Keine Sorge Billi, da bin ich schon seit ein paar Wochen drin 😊

Lasst zosano nicht aus den Augen, fängt an sich für den pdufa Termin warm zu laufen

Bei Sorrento bin ich immer etwas vorsichtig, weil zweistellige Kursgewinne schnell wieder ab verkauft wurden. Aber die letzten Handelstage sehen super aus!

Sauber! 😉 BioCryst gucke ich lieber erstmal nur. Sieht irgendwie merkwürdig aus. Das so eine Meldung den Kurs nicht fliegen lässt ist mir auch ein Rätsel.

Weed, Aquestive zu 5,69 👍.

Ich denke auch, dass esbei guter Nachrichtenlage, 6$.

f.ool

Fast Track hat sich sehr kurz am Kurs gezeigt (ca. 20%) und ist wieder abverkauft worden. BCRX wird, über den großen Teich als Kandidat für Covid-19 angesehen. The case for Biocryst Pharmaceuticals Biocryst Pharmaceuticals is also on the COVID-19 stage with its antiviral drug galidesivir. The company announced earlier this month that it has begun a phase 2 clinical study in Brazil evaluating the drug in treating COVID-19. Galidesivir was originally developed for treating Marburg virus disease but has shown potential in other viruses. Unlike Moderna, though, Biocryst already has one product on the market. The Food and Drug Administration (FDA) approved Rapivab in 2014 for treating influenza in adults and in 2017 for treating influenza in pediatric patients two years and older. Rapivab hasn't been a huge commercial success story for Biocryst, however, with the company recording sales of $13.9 million from the drug in the fourth quarter of 2019. The big story for Biocryst is berotralstat. Earlier this year, the company filed for U.S. and Japanese approvals of the drug for the prevention of hereditary angioedema (HAE) attacks. HAE is an inherited disorder where patients experience recurrent attacks of severe swelling, often in the arms, legs, and face. Biocryst already has a partner for the commercialization of berotralstat in Japan. Torii Pharmaceutical paid the biotech $22 million upfront for the Japanese rights to the HAE drug. In addition, Biocryst stands to receive up to $20 million in milestone payments plus tiered royalties ranging from the mid-teens to up to 40% of Japanese net sales of berotralstat. The company is evaluating a liquid form of berotralstat in a phase 2 clinical study for treating acute HAE. Its pipeline also includes two other early-stage programs: oral Factor D inhibitor BCX9930 and BCX9250, which targets rare connective tissue disease fibrodysplasia ossificans progressiva (FOP). Quelle: https://www.fool.com/investing/2020/04/25/better-buy-moderna-vs-biocryst-pharmaceuticals.aspx

Und am 06.08 ist Financial Results.